Cystine-binding thiol drugs include alpha-mercaptopropionylglycine, also known as tiopronin (Thiola[R]) and D-penicillamine.
Thiol derivatives, such as tiopronin and D-penicillamine, cleave cystine into two cysteine moieties and combine with cysteine to form a highly soluble disulfide compound, decreasing the excretion of poorly solublefree cystine and increasing its solubility.
Imprimis will supply all formulations included under its Imprimis Cares formulary including the patent-pending tiopronin
delayed-release formulations, a lower cost alternative to Thiola; pyrimethamine and leucovorin formulations, an alternative to Daraprim; the company's proprietary Dropless Therapy injectable and LessDrops topical formulations; as well as additional compounded drug formulations for patient populations that may not have available alternatives to increasingly expensive branded medications and lacking meaningful generic competition.
Most of the latter patients received conventional liver-protecting treatment, for instance, polyene phosphatidylcholine, tiopronin
on Hartley albino guinea pigs, found beneficial effects of alpha-tocopherol and tiopronin on cisplatin-induced ototoxicity.
Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity.
(Thiola), which reduces the amount of cystine in the urine.
(Thiola) may be used to reduce the amount of cystine in the urine.
Streem called tiopronin
(Thiola) the drug of choice because it is less likely than D-penicillamine to cause side effects.
She was prescribed tiopronin (Thiola[R]) 200 mg twice daily, and was instructed to limit her sodium and protein intake.
interacted with the International Cystinuria Foundation, where she learned more about cystinuria and received a more detailed explanation regarding the use of tiopronin and the steps needed to become stone-free.
In May 2016, Imprimis introduced its patent-pending tiopronin
delayed release compounded formulations, a lower-cost alternative to Thiola, representing an estimated cost savings of over 80 percent compared to Thiola, a chronic care drug which can cost in excess of $150,000 per year per patient.